SCHEMBL7167682

SCHEMBL7167682

CCOC(=O)c1cnc2c(CC)cc(C#N)cc2c1NCc1ccc(Br)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 7/20 0.73
MAPT P10636 7/20 0.47
ALDH1A1 P00352 6/20 0.47
LMNA P02545 4/20 0.47
HPGD P15428 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAPK1 P28482 1/20 0.47
KDM4E B2RXH2 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
GAA P10253 3/20 0.46
PDE4B Q07343 1/20 0.46
RXFP1 Q9HBX9 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
POLB P06746 2/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7160498 0.93 PDE5A (0.75) PDE5AMAPTALDH1A1LMNAHPGD
SCHEMBL7623212 0.91 PDE5A (0.64) PDE5AMAPTALDH1A1LMNAMAPK1
SCHEMBL7164927 0.91 PDE5A (0.73) PDE5AMAPTALDH1A1LMNAHPGD
SCHEMBL7167673 0.91 PDE5A (0.73) PDE5AMAPTALDH1A1LMNAHPGD
SCHEMBL7168877 0.90 PDE5A (0.77) PDE5AMAPTALDH1A1LMNAHPGD
SCHEMBL7165631 0.89 PDE5A (0.73) PDE5AMAPTALDH1A1LMNAHPGD
SCHEMBL7164783 0.89 PDE5A (0.71) PDE5AMAPTALDH1A1LMNAHPGD
SCHEMBL7163487 0.89 PDE5A (0.70) PDE5AMAPTALDH1A1LMNAHPGD
SCHEMBL7170790 0.88 PDE5A (0.69) PDE5AMAPTALDH1A1LMNAHPGD
SCHEMBL7163184 0.88 PDE5A (0.73) PDE5AMAPTALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225128-A1 Quinoline inhibitors of cGMP phosphodiesterase BI YINGZHI (US) 2003-12-04 US claimed
US-6576644-B2 Treating sexual dysfunction including erectile dysfunction, diabetes melitus, gastrointestinal disorders, including gastric paresis and cardiovascular disorders; cyclic guanosine 3',5'-monophosphate (cGMP) BRISTOL-MYERS SQUIBB CO. 2003-06-10 US claimed
US-20020177587-A1 Quinoline inhibitors of cGMP phosphodiesterase BRISTOL-MYERS SQUIBB COMPANY 2002-11-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225128-A1 Quinoline inhibitors of cGMP phosphodiesterase PDE5A, PDE3A, PDE2A PDE5A 1/4885MAPT 4486/4885ALDH1A1 301/4885
US-20020177587-A1 Quinoline inhibitors of cGMP phosphodiesterase PDE5A, PDE2A, PDE3A PDE5A 1/4885MAPT 4376/4885ALDH1A1 709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.